Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 186

Results For "NITI"

3573 News Found

Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial
Clinical Trials | April 06, 2024

Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial


Aster DM Healthcare concludes separation of India and GCC businesses
Healthcare | April 05, 2024

Aster DM Healthcare concludes separation of India and GCC businesses

The company plans to add 1700 beds by FY27 through the organic route


Dabur India expects mid-single digit revenue growth in Q4
News | April 05, 2024

Dabur India expects mid-single digit revenue growth in Q4

International Business is expected to register double-digit growth in constant currency terms


Max CMD Abhay Soi is new president of NATHEALTH
People | April 04, 2024

Max CMD Abhay Soi is new president of NATHEALTH

New leadership team announced at NATHEALTH Annual General Meeting 2024


EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes
Drug Approval | April 03, 2024

EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia


Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO  International Non-proprietary Names
News | April 02, 2024

Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names

Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus


MTD acquires Ypsomed's pen needle and BGM businesses
Medical Device | April 01, 2024

MTD acquires Ypsomed's pen needle and BGM businesses

This acquisition enables MTD to open new, strategic markets


Venus Remedies receives Rs. 2.50 crore under PLI scheme
Policy | April 01, 2024

Venus Remedies receives Rs. 2.50 crore under PLI scheme

The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme